Category Regulatory

Lantern Pharma Receives FDA Rare Pediatric Disease Designations for LP-184 in Ultra-Rare Children’s Cancers

Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven biotech company focused on developing targeted cancer therapies through its proprietary RADR® AI and machine learning platform, announced that the FDA has granted it three Rare Pediatric Disease Designations (RPDD). These designations cover…

Read MoreLantern Pharma Receives FDA Rare Pediatric Disease Designations for LP-184 in Ultra-Rare Children’s Cancers

WHO Endorses CINtec PLUS Test, Highlighting Roche’s Role in Cervical Cancer Care

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the World Health Organization (WHO) has included dual-stain cytology testing in its updated cervical cancer prevention guidelines. The Roche CINtec® PLUS Cytology test is currently the only FDA-approved and CE-marked dual-stain test…

Read MoreWHO Endorses CINtec PLUS Test, Highlighting Roche’s Role in Cervical Cancer Care

US Approves Sarclisa as First Anti-CD38 Therapy for Non-Transplant Multiple Myeloma Patients

The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment for adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell…

Read MoreUS Approves Sarclisa as First Anti-CD38 Therapy for Non-Transplant Multiple Myeloma Patients

Fasenra Receives U.S. Approval for Treating Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca’s Fasenra (benralizumab) has received U.S. approval for treating adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare and potentially fatal immune-mediated vasculitis that can damage multiple organs. This approval from the U.S. Food and Drug Administration (FDA) is…

Read MoreFasenra Receives U.S. Approval for Treating Eosinophilic Granulomatosis with Polyangiitis

Glycomine Granted FDA Fast Track Designation for GLM101 in PMM2-CDG Treatment

Glycomine, Inc., a biotechnology company specializing in treatments for rare diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to GLM101, a mannose-1-phosphate replacement therapy being developed to treat phosphomannomutase 2-congenital disorder of…

Read MoreGlycomine Granted FDA Fast Track Designation for GLM101 in PMM2-CDG Treatment

FDA Approves Novartis Kisqali for Reducing Early Breast Cancer Recurrence

Novartis announced today that the US Food and Drug Administration (FDA) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and…

Read MoreFDA Approves Novartis Kisqali for Reducing Early Breast Cancer Recurrence

FDA Approves OCREVUS ZUNOVO First 10-Minute Biannual Injection for Multiple Sclerosis

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). This new formulation is…

Read MoreFDA Approves OCREVUS ZUNOVO First 10-Minute Biannual Injection for Multiple Sclerosis